• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics down on tightened guidance — but it hits milestone on 365-day implantable CGM

November 9, 2022 By Chris Newmarker

Senseonics logoSenseonics (NYSE American: SENS) reported a third-quarter revenue beat, but its stock took a hit amid tightened full-year revenue guidance.

The Germantown, Maryland–based maker of implantable continuous glucose management systems lost $60.4 million, or 13¢ per share, off $4.6 million in revenue for the quarter ended Sept. 30, 2022. In contrast, Senseonics saw a profit of $42.9 million, or 8¢ per share, off revenue of $3.5 million during Q3 2021.

Wall Street analysts had expected a loss of 4¢ off $4.31 million in revenue during the quarter.

With its commercial partner Ascensia Diabetes Care, Senseonics has transitioned worldwide to its 180-day Eversense E3.  The companies have launched a collaboration with the Nurse Practitioner Group (NPG) to broaden access to the device.

“Having launched the partnership with the Nurse Practitioner Group to expand access with in-home and in-office insertion options, we continue to work with Ascensia to execute and build the foundation for increased adoption of Eversense,” Senseonics CEO Tim Goodnow said in a news release.

Senseonics moves forward on a 365-day CGM

Next up, Senseonics has completed enrollment of a pivotal trial for a 365-day sensor configuration. The company also submitted an IDE for enrollment of a pediatric cohort.

Goodnow spoke of the achievement of key milestones in clinical and R&D programs. “We continue to advance our initiatives towards delivering the benefits of long-term implantable CGM to more patients.”

BTIG analysts think FDA approval of a 365-day implantable CGM could arrive sometime in mid-2024.

Senseonics tightening guidance

Senseonics now expects full-year revenue in the $15–17 million range. The previous guidance was $14–18 million. CFO Rick Sullivan cited the macroeconomic environment, including the present foreign exchange environment impacting European revenues. (Many U.S. companies have found a strong dollar affecting exports.)

Marie Thibault and Sam Eiber at BTIG kept their Neutral rating on SENS shares because of valuation concerns. At the same time, they also were upbeat about the company: “There were many positives we came away with this quarter — the early E3 traction in the U.S., broadening access and awareness for the technology, the diversity of customers joining the platform (over half of users have Type 2 diabetes), and advances in clinical trial development.”

Investors reacted by sending SENS shares down more than 11% to $1.06 apiece by midday trading today. Our sister site MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up slightly.

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS